Cargando…

Clinical pharmacy services for tuberculosis management: a systematic review

Objective: This study aims to systematically review the content and potential effects of clinical pharmacy services in tuberculosis (TB) care management. Methods: Searches were performed in PubMed, Embase, Cochrane, Scopus, and Web of Science databases following Preferred Reporting Items for Systema...

Descripción completa

Detalles Bibliográficos
Autores principales: Iskandar, D., Suryanegara, F. D. A., van Boven, J. F. M., Postma, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360183/
https://www.ncbi.nlm.nih.gov/pubmed/37484021
http://dx.doi.org/10.3389/fphar.2023.1186905
_version_ 1785076046758936576
author Iskandar, D.
Suryanegara, F. D. A.
van Boven, J. F. M.
Postma, M. J.
author_facet Iskandar, D.
Suryanegara, F. D. A.
van Boven, J. F. M.
Postma, M. J.
author_sort Iskandar, D.
collection PubMed
description Objective: This study aims to systematically review the content and potential effects of clinical pharmacy services in tuberculosis (TB) care management. Methods: Searches were performed in PubMed, Embase, Cochrane, Scopus, and Web of Science databases following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study characteristics and outcomes were extracted, and clinical pharmacy service components were characterized using the Descriptive Elements of Pharmacist Intervention Characterization Tool. Results: Twenty articles were included for full-text assessment, of which 10 fulfilled inclusion criteria, comprising 1,168 patients (N = 39 to 258 per study). These articles included five prospective cohort studies, two case–control studies, two quasi-experimental studies, and one cross-sectional study. Intervention foci within clinical pharmacy services were medication adherence (50%), medication safety (40%), education to patients/caregivers regarding needs/beliefs (30%), optimizing medication/therapy effectiveness (30%), emphasizing HRQoL (10%), and drug selections (10%). The three most frequently applied interventions were drug information/patient counseling (80%), adverse drug reaction monitoring (50%), and drug use evaluation (20%). Based on the World Health Organization (WHO) outcome classification, treatment success ranged from 72% to 93%, with higher cure outcomes (53%–86%) than treatment completion (7%–19%). Other outcomes, including isoniazid metabolites, medication counts, sputum conversion, adherence/compliance, knowledge, and quality of life, were better in the intervention group than those in comparator groups, and/or they improved over time. Risk of bias analysis indicated that the included studies were not comparable to a randomized clinical trial. Conclusion: Clinical pharmacy services as single or composite interventions potentially improve TB outcomes, but its evidence is still inconsistent and limited due to the lack of randomized controlled studies using the WHO outcome classification. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=199028, identifier CRD42020199028.
format Online
Article
Text
id pubmed-10360183
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103601832023-07-22 Clinical pharmacy services for tuberculosis management: a systematic review Iskandar, D. Suryanegara, F. D. A. van Boven, J. F. M. Postma, M. J. Front Pharmacol Pharmacology Objective: This study aims to systematically review the content and potential effects of clinical pharmacy services in tuberculosis (TB) care management. Methods: Searches were performed in PubMed, Embase, Cochrane, Scopus, and Web of Science databases following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Study characteristics and outcomes were extracted, and clinical pharmacy service components were characterized using the Descriptive Elements of Pharmacist Intervention Characterization Tool. Results: Twenty articles were included for full-text assessment, of which 10 fulfilled inclusion criteria, comprising 1,168 patients (N = 39 to 258 per study). These articles included five prospective cohort studies, two case–control studies, two quasi-experimental studies, and one cross-sectional study. Intervention foci within clinical pharmacy services were medication adherence (50%), medication safety (40%), education to patients/caregivers regarding needs/beliefs (30%), optimizing medication/therapy effectiveness (30%), emphasizing HRQoL (10%), and drug selections (10%). The three most frequently applied interventions were drug information/patient counseling (80%), adverse drug reaction monitoring (50%), and drug use evaluation (20%). Based on the World Health Organization (WHO) outcome classification, treatment success ranged from 72% to 93%, with higher cure outcomes (53%–86%) than treatment completion (7%–19%). Other outcomes, including isoniazid metabolites, medication counts, sputum conversion, adherence/compliance, knowledge, and quality of life, were better in the intervention group than those in comparator groups, and/or they improved over time. Risk of bias analysis indicated that the included studies were not comparable to a randomized clinical trial. Conclusion: Clinical pharmacy services as single or composite interventions potentially improve TB outcomes, but its evidence is still inconsistent and limited due to the lack of randomized controlled studies using the WHO outcome classification. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=199028, identifier CRD42020199028. Frontiers Media S.A. 2023-07-07 /pmc/articles/PMC10360183/ /pubmed/37484021 http://dx.doi.org/10.3389/fphar.2023.1186905 Text en Copyright © 2023 Iskandar, Suryanegara, van Boven and Postma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Iskandar, D.
Suryanegara, F. D. A.
van Boven, J. F. M.
Postma, M. J.
Clinical pharmacy services for tuberculosis management: a systematic review
title Clinical pharmacy services for tuberculosis management: a systematic review
title_full Clinical pharmacy services for tuberculosis management: a systematic review
title_fullStr Clinical pharmacy services for tuberculosis management: a systematic review
title_full_unstemmed Clinical pharmacy services for tuberculosis management: a systematic review
title_short Clinical pharmacy services for tuberculosis management: a systematic review
title_sort clinical pharmacy services for tuberculosis management: a systematic review
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360183/
https://www.ncbi.nlm.nih.gov/pubmed/37484021
http://dx.doi.org/10.3389/fphar.2023.1186905
work_keys_str_mv AT iskandard clinicalpharmacyservicesfortuberculosismanagementasystematicreview
AT suryanegarafda clinicalpharmacyservicesfortuberculosismanagementasystematicreview
AT vanbovenjfm clinicalpharmacyservicesfortuberculosismanagementasystematicreview
AT postmamj clinicalpharmacyservicesfortuberculosismanagementasystematicreview